In the present study, we showed a trend toward increased expression of CEACAM-1 and CD155 on tumor cells after anti-PD-1 therapy in patients with unresectable advanced or recurrent G/GEJ cancer (p = 0.059 and p = 0.093, respectively) (Figure 5g,h). Here, CEACAM1 is linked to neoplasm.